AZD6738
Phase 1UNKNOWN 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Solid Tumour Refractory to Conventional Treatment
Conditions
Solid Tumour Refractory to Conventional Treatment
Trial Timeline
Jul 1, 2014 → Dec 30, 2025
NCT ID
NCT02223923About AZD6738
AZD6738 is a phase 1 stage product being developed by AstraZeneca for Solid Tumour Refractory to Conventional Treatment. The current trial status is unknown. This product is registered under clinical trial identifier NCT02223923. Target conditions include Solid Tumour Refractory to Conventional Treatment.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03770429 | Phase 1 | Active |
| NCT02223923 | Phase 1 | UNKNOWN |
Competing Products
20 competing products in Solid Tumour Refractory to Conventional Treatment